CN Patent

CN102107008B — 用于治疗癌症的dna损伤修复抑制剂

Assigned to Institute of Cancer Research Royal Cancer Hospital · Expires 2013-04-03 · 13y expired

What this patent protects

本发明涉及认同在HR依赖的DNA DSB修复缺陷细胞中碱基切除修复途径的抑制是选择性致死的。在此提供涉及使用靶向碱基切除修复组分(如PARP)的抑制剂来治疗HR依赖的DNA DSB修复缺陷的癌症的方法和手段。

USPTO Abstract

本发明涉及认同在HR依赖的DNA DSB修复缺陷细胞中碱基切除修复途径的抑制是选择性致死的。在此提供涉及使用靶向碱基切除修复组分(如PARP)的抑制剂来治疗HR依赖的DNA DSB修复缺陷的癌症的方法和手段。

Drugs covered by this patent

Patent Metadata

Patent number: CN102107008B
Jurisdiction: CN
Classification: —
Expires: 2013-04-03
Drug substance claim: No
Drug product claim: No
Assignee: Institute of Cancer Research Royal Cancer Hospital
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.